Ricardo Alexandre Azevedo

Ricardo Alexandre Azevedo

Auto-generated profile, based on publicly available information

Ricardo Alexandre Azevedo

Departament of Immunology, Laboratory of Tumor Immunology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CFCarlos Rogerio Figueiredo
Carlos Rogerio Figueiredo
RARicardo A. Azevedo
Ricardo A. Azevedo
SMSasha Mousdell
Sasha Mousdell
PLPedro Tulio de Resende Lara
Pedro Tulio de Resende Lara
LILucy Ireland
Lucy Ireland
AMAinhoa Mielgo
Ainhoa Mielgo
Mounting an effective immune response against cancer requires the activation of innate and adaptive immune cells. Metastatic melanoma is the most aggressive form of skin cancer. While immunotherapies have shown a remarkable success in melanoma treatment, patients develop resistance by mechanisms that include the establishment of an immune suppressive tumor microenvironment. Thus, understanding how metastatic melanoma cells suppress the immune system is vital to develop effective immunotherapies against this disease. In this study, we find that macrophages (MOs) and dendritic cells (DCs) are suppressed in metastatic melanoma and that the Ig-CDR-based peptide C36L1 is able to restore MOs and DCs’ antitumorigenic and immunogenic functions and to inhibit metastatic growth in lungs. Specifically, C36L1 treatment is able to repolarize M2-like immunosuppressive MOs into M1-like antitumorigenic MOs, and increase the number of immunogenic DCs, and activated cytotoxic T cells, while reducing the number of regulatory T cells and monocytic myeloid-derived suppressor cells in metastatic lungs. Mechanistically, we find that C36L1 directly binds to the MIF receptor CD74 which is expressed on MOs and DCs, disturbing CD74 structural dynamics and inhibiting MIF signaling on these cells. Interfering with MIF–CD74 signaling on MOs and DCs leads to a decrease in the expression of immunosuppressive factors from MOs and an increase in the capacity of DCs to activate cytotoxic T cells. Our findings suggest that interfering with MIF–CD74 immunosuppressive signaling in MOs and DCs, using peptide-based immunotherapy can restore the antitumor immune response in metastatic melanoma. Our study provides the rationale for further development of peptide-based therapies to restore the antitumor immune response in metastatic melanoma.

10 June 2022 in Science Immunology
Verified
Journal Article
Closed access
CHCheng-En Hsieh
Cheng-En Hsieh
SKSunil Krishnan
Sunil Krishnan
RWRen-Chin Wu
Ren-Chin Wu
ABAkash R. Boda
Akash R. Boda
ALArthur Liu
Arthur Liu
MCMichael A. Curran
Michael A. Curran
Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-associated antigen (TAA)–expressing CRC cells systemically. However, abscopal tumor remissions are extremely rare, and the postirradiation immune escape mechanisms in CRC remain elusive. Here, we found that irradiated CRC cells used ATR-mediated DNA repair signaling pathway to up-regulate both CD47 and PD-L1, which through engagement of SIRPα and PD-1, respectively, prevented phagocytosis by antigen-presenting cells and thereby limited TAA cross-presentation and innate immune activation. This postirradiation CD47 and PD-L1 up-regulation was observed across various human solid tumor cells. Concordantly, rectal cancer patients with poor responses to neoadjuvant RT exhibited significantly elevated postirradiation CD47 levels. The combination of RT, anti-SIRPα, and anti–PD-1 reversed adaptive immune resistance and drove efficient TAA cross-presentation, resulting in robust TAA-specific CD8 T cell priming, functional activation of T effectors, and increased T cell clonality and clonal diversity. We observed significantly higher complete response rates to RT/anti-SIRPα/anti–PD-1 in both irradiated and abscopal tumors and prolonged survival in three distinct murine CRC models, including a cecal orthotopic model. The efficacy of triple combination therapy was STING dependent as knockout animals lost most benefit of adding anti-SIRPα and anti–PD-1 to RT. Despite activation across the myeloid stroma, the enhanced dendritic cell function accounts for most improvements in CD8 T cell priming. These data suggest ATR-mediated CD47 and PD-L1 up-regulation as a key mechanism restraining radiation-induced immune priming. RT combined with SIRPα and PD-1 blockade promotes robust antitumor immune priming, leading to systemic tumor regressions.

1 November 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
NGNatalia Girola
Natalia Girola
CFCarlos Rogerio Figueiredo
Carlos Rogerio Figueiredo
CFCamyla F. Farias
Camyla F. Farias
RARicardo A. Azevedo
Ricardo A. Azevedo
AFAdilson K. Ferreira
Adilson K. Ferreira
JLJoao Henrique Ghilardi Lago
Joao Henrique Ghilardi Lago

1 June 2015 in Peptides
Verified
Journal Article
Closed access
RARicardo A. de Azevedo
Ricardo A. de Azevedo
CFCarlos Rogerio Figueiredo
Carlos Rogerio Figueiredo
AFAdilson K. Ferreira
Adilson K. Ferreira
AMAlisson L. Matsuo
Alisson L. Matsuo
MMMariana H. Massaoka
Mariana H. Massaoka
ILIvo Lebrun
Ivo Lebrun

1 June 2016 in Phytomedicine
Verified
Journal Article
Closed access
PDPaulo De-Sá-Júnior
Paulo De-Sá-Júnior
DCDiana Aparecida Dias Câmara
Diana Aparecida Dias Câmara
ACAndré Santos Costa
André Santos Costa
JRJorge Luis Maria Ruiz
Jorge Luis Maria Ruiz
DLDebora Levy
Debora Levy
AFAdilson Kleber Ferreira
Adilson Kleber Ferreira

18 November 2015 in BioMetals
Verified
Journal Article
Closed access
PDF file
LTLenka V. Tamayo
Lenka V. Tamayo
LGLigiane R. Gouvea
Ligiane R. Gouvea
ASAnna C. Sousa
Anna C. Sousa
RARonniel M. Albuquerque
Ronniel M. Albuquerque
STSarah Fernandes Teixeira
Sarah Fernandes Teixeira
HBHeloisa Beraldo
Heloisa Beraldo